Incyte (INCY) EBT Growth (3y) (2013 - 2026)

Incyte (INCY) EBT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Incyte 23.33 Bn 19.32 Bn 1.17 Bn 87.82%

Historic Data

Download Data
DateValue
Mar 31, 2026 87.82%
Dec 31, 2025 69.12%
Sep 30, 2025 48.06%
Jun 30, 2025 34.49%
Mar 31, 2025 49.18%
Dec 31, 2024 37.75%
Sep 30, 2024 -9.26%
Jun 30, 2024 -62.25%
Mar 31, 2024 50.47%
Dec 31, 2023 17.25%
Sep 30, 2023 309.46%
Jun 30, 2023 -3.33%
Mar 31, 2023 27.52%
Dec 31, 2022 -13.83%
Sep 30, 2022 0.13%
Jun 30, 2022 28.28%
Mar 31, 2022 -12.17%
Dec 31, 2021 19.28%
Sep 30, 2021 89.10%
Jun 30, 2021 47.02%